A new study has revealed that a blood based test can now tell that threatened preterm labor (TPTL) women's are ready for the birth or not.
Professor Stephen Lye said that it will help in properly attending the pregnant women who actually needs the appropriate medical care while women in false labor will receive supportive care and be discharged and it will avoid unnecessarily hospitalization of women.
Fetal fibronectin (fFN), the current preterm labor diagnostic test, is easily influenced by factors that can provide false results; therefore, many women are ineligible for fFN testing.
So to study the blood gene expression associated with the spontaneous premature birth within 48 hours in women admitted with TPTL, the scientist used microarrays.
The study found that set of nine genes when coupled with clinical blood data, could classify whether 70% of hospitalized women would or would not have a spontaneous preterm birth within 48 hours.
The study was published in the open access journal Plos One.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
